Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Neeraj Agarwal,Simon Chowdhury,Anders Bjartell,Byung Ha Chung,Andrea J. Pereira de Santana Gomes,Robert Given,Álvaro Juárez,Axel S. Merseburger,Mustafa Ozguroglu,Hirotsugu Uemura,Dingwei Ye,Sabine Brookman-May,Suneel Mundle,Sharon Anne McCarthy,Florence Lefresne,S. Dibaj,Katherine B Bevans,Kim N. Chi

Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

2021

Neeraj Agarwal
Simon Chowdhury
Anders Bjartell
Byung Ha Chung
Andrea J. Pereira de Santana Gomes
Robert Given
Álvaro Juárez
Axel S. Merseburger
Mustafa Ozguroglu
Hirotsugu Uemura
Dingwei Ye
Sabine Brookman-May
Suneel Mundle
Sharon Anne McCarthy
Florence Lefresne
S. Dibaj
Katherine B Bevans
Kim N. Chi

5068Background: The phase 3 TITAN study evaluated APA vs PBO in pts with mCSPC receiving ADT. At primary analysis with 22.7 mo median follow-up, APA significantly improved overall survival (OS) and...

Keywords:

Apalutamide
Internal medicine
Medicine
Androgen deprivation therapy
health related quality of life
Placebo
overall survival
in patient
Oncology
Castration-sensitive prostate cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations